

Signaling During Platelet Adhesion and Activation

Zhenyu Li, M. Keegan Delaney, Kelly A. O'Brien, Xiaoping Du

Abstract—Upon vascular injury, platelets are activated by adhesion to adhesive proteins, such as von Willebrand factor and collagen, or by soluble platelet agonists, such as ADP, thrombin, and thromboxane A_2 . These adhesive proteins and soluble agonists induce signal transduction via their respective receptors. The various receptor-specific platelet activation signaling pathways converge into common signaling events that stimulate platelet shape change and granule secretion and ultimately induce the “inside-out” signaling process leading to activation of the ligand-binding function of integrin $\alpha_{IIb}\beta_3$. Ligand binding to integrin $\alpha_{IIb}\beta_3$ mediates platelet adhesion and aggregation and triggers “outside-in” signaling, resulting in platelet spreading, additional granule secretion, stabilization of platelet adhesion and aggregation, and clot retraction. It has become increasingly evident that agonist-induced platelet activation signals also cross talk with integrin outside-in signals to regulate platelet responses. Platelet activation involves a series of rapid positive feedback loops that greatly amplify initial activation signals and enable robust platelet recruitment and thrombus stabilization. Recent studies have provided novel insight into the molecular mechanisms of these processes. (*Arterioscler Thromb Vasc Biol.* 2010;30:2341-2349.)

Key Words: adhesion molecules ■ G proteins ■ platelets ■ receptors ■ signal transduction

Blood platelets play important roles in hemostasis, thrombosis, wound healing, atherosclerosis, inflammation, immunity, and tumor metastasis.^{1–4} Of these functions, the primary physiological function of platelets is to form hemostatic thrombi that prevent blood loss and maintain vascular integrity. This function must be tightly regulated because dysregulated thrombus formation (thrombosis) causes blockage of blood vessels, leading to ischemia. Thrombotic diseases, such as heart attack and ischemic stroke, are a leading cause of mortality in the modern world. Thus, platelets in normal circulation are in a nonadherent “resting” state and become activated at sites of vascular injury after exposure to immobilized adhesive proteins or soluble platelet agonists. The signaling process that occurs during platelet activation can be classified into 3 stages: (1) the interaction of agonists with their respective platelet receptors and receptor-mediated early platelet activation signaling, (2) the intermediate common signaling events, and (3) integrin activation (inside-out signaling) and outside-in signaling. However, platelet activation is a dynamic process involving multiple feedback loops and cross talk between different pathways. In particular, platelets rely on endogenous secondary signal amplification mechanisms and their regulation to achieve a relevant level of response to vascular injury.

In the past 3 decades, remarkable progress has been made in identifying the fundamental mechanisms of platelet function and signaling pathways of platelet activation, which has

greatly facilitated the development of antiplatelet therapeutics for preventing and treating thrombotic diseases.^{1,2} However, the agents that block fundamental platelet functions, such as integrin blockers, while having potent antithrombotic effects, cause bleeding in approximately 0.5% to 1.5% of patients receiving such compounds. The cyclooxygenase inhibitor (aspirin) and ADP purinergic receptor P2Y₁₂ antagonists in use are also associated with problems such as drug resistance and bleeding. A better understanding of intracellular signaling during platelet adhesion and activation will be helpful for the development of new generations of antiplatelet therapies.

Adhesion Receptor–Mediated Platelet Activation and Signaling

Platelet adhesion receptors are the key initiators of platelet activation at sites of vascular injury where platelets become exposed to adhesive proteins in the matrix or on endothelial cells (Figure 1). Interestingly, despite significant differences in their functions and signaling pathways, several major platelet adhesion receptors share many similarities in their signal transduction mechanisms. For example, signal transduction through the glycoprotein Ib–IX–V complex (GPIb–IX), GPVI, and integrins all involve Src family kinases (SFKs), phosphoinositide 3-kinases (PI3Ks), and the immunoreceptor tyrosine-based activation motif (ITAM) signaling pathway.

Received on: September 21, 2010; final version accepted on: October 6, 2010.

From the Department of Medicine (Z.L.), University of Kentucky, Lexington; and the Department of Pharmacology (M.K.D., K.A.O., and X.D.), University of Illinois at Chicago, Chicago, Ill.

Correspondence to Xiaoping Du, MD, PhD, the Department of Pharmacology, University of Illinois at Chicago, 835 S Wolcott Ave, Chicago, IL 60612. E-mail xdu@uic.edu

© 2010 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.110.207522




Figure 1. Signaling pathways of 3 major platelet adhesion receptors. sGC, soluble guanylyl cyclase; eNOS, endothelial NO synthase.

Collagen/GPVI-Mediated Platelet Activation Signaling

Platelets express several collagen receptors.⁵ Of these receptors, integrin $\alpha_2\beta_1$ is important for platelet adhesion to collagen, whereas GPVI is required for collagen-induced platelet activation. GPVI is a member of the immunoglobulin superfamily and is noncovalently coupled to the Fc receptor γ chain (FcR γ).⁶ Upon cross-linking of GPVI by its ligand, the ITAM (a conserved sequence, YxxL/I-X₆ to 8-XXL/I, originally important in T-cell antigen receptor signaling⁷) within the FcR γ cytoplasmic domain is tyrosine phosphorylated by SFKs (mainly Lyn and Fyn) bound to the cytoplasmic domain of GPVI.^{8,9} SFK activation is important for GPVI-mediated platelet activation and involves CD148, a receptorlike protein tyrosine phosphatase that was reported to dephosphorylate the C-terminal inhibitory tyrosines of SFKs.¹⁰

ITAM phosphorylation leads to binding and activation of the tyrosine kinase Syk, which phosphorylates downstream targets, such as the transmembrane adapter linker for activated T cells (LAT) and the Src homology 2 domain-containing leukocyte phosphoprotein of 76-kDa (SLP-76). This induces the formation of a signaling complex, including LAT, SLP-76, Bruton tyrosine kinase (Btk), Gads, and phospholipase C γ (PLC γ) 2, which further activates PLC γ 2,^{11,12} leading to thromboxane A₂ (TXA₂) synthesis, granule secretion, and integrin activation (Figure 1). The pleckstrin homology (PH) domain of PLC γ 2 also interacts with the PI3K product phosphatidylinositol 3,4,5-trisphosphate, which facilitates PLC γ 2 recruitment to the plasma membrane and activation.^{13–15} ITAM signaling is negatively regulated by signals transduced from platelet endothelial cell adhesion molecule-1 (PECAM-1).¹⁶

von Willebrand Factor/GPIb-IX-Mediated Platelet Activation

Under high shear rate flow conditions present in arteries and arterioles, initial platelet adhesion requires the binding of immobilized von Willebrand factor (VWF) to its platelet receptor, GPIb-IX.^{17–19} VWF forms a so-called “catch bond” or “flex bond” with the ligand-binding domain of GPIb-IX,^{20,21} allowing transient platelet adhesion under high shear stress. VWF/GPIb-IX interaction also induces platelet activation signaling events, leading to integrin activation and integrin-dependent stable platelet adhesion and aggregation.¹⁹ In addition, GPIb-IX binds thrombin and sensitizes platelets to low-dose thrombin.

There has been evidence that GPIb-IX is associated with the ITAM receptors Fc γ RIIA²² or FcR γ .²³ Genetic deletion of ITAM signaling molecules, such as FcR γ , Syk, LAT, SLP-76, and Btk, abolishes the TXA₂ and secretion-dependent second wave of platelet aggregation induced by VWF/biotroctin in washed mouse platelets.^{24,25} However, loss of FcR γ and LAT does not appear to affect GPIb-IX-dependent integrin activation and TXA₂ synthesis,^{24,26} both of which involve the mitogen-activated protein kinase (MAPK) pathway.^{27–29} Similarly, Syk is not required for GPIb-IX- and integrin-dependent stable platelet adhesion to VWF under shear stress.³⁰ Considering the importance of the ITAM pathway in granule secretion and integrin outside-in signaling, it likely functions as an important signal amplification mechanism in GPIb-IX signaling.

The cytoplasmic domain of the GPIb α chain reportedly interacts with SFKs and PI3Ks,^{23,31} which are important for transmitting the “early” activation signals from GPIb-IX,^{24,26,31–33} leading to calcium elevation³⁴ and integrin activation independent of other receptors.^{26,30,33} The SFK Lyn is required for activation of PI3K and its downstream effector Akt, leading to integrin activation.^{24,30,33} Interestingly, VWF/GPIb-IX interaction induces elevation of intracellular cGMP levels^{35,36} and sequential activation of cGMP-dependent protein kinase (PKG) and the MAPKs, p38, and extracellular signal-regulated kinase (ERK).^{27,28,35} The cGMP signaling pathway is activated downstream from the Lyn/PI3K/Akt pathway,^{30,33} which activates NO synthase. NO may be important for VWF-induced cGMP elevation,^{35,36} although SFK-dependent NO-independent soluble guanylyl cyclase activation has been proposed.³⁷ A role for the PKG/MAPK signaling pathway in GPIb-IX-mediated integrin activation has been shown using inhibitors and knockout mice.^{27,28,35} Together, these data reveal that the Lyn/PI3K/Akt/NO/cGMP/PKG/MAPK signaling pathway plays an important role in GPIb-IX-mediated platelet activation. The role of NO and cGMP in platelet activation is biphasic.³⁵ The low concentrations of NO/cGMP synthesized during platelet activation are stimulatory, whereas high concentrations of NO and cGMP inhibit platelet activation. The biphasic role of the NO/cGMP pathway may serve to stimulate robust hemostatic thrombus formation at sites of vascular injury while preventing overgrowth of the thrombus.




Figure 2. GPCR-coupled platelet activation signaling. PDE3, phosphodiesterase 3; p115RhoGEF, p115 Rho guanine nucleotide exchange factor.

Platelet Activation and Signaling Mediated by G-Protein–Coupled Receptors

A variety of soluble platelet agonists are released from damaged cells (eg, ADP), produced during coagulation (eg, thrombin) and inflammation (eg, platelet-activating factor), and enriched in atherosclerotic plaques (eg, lysophosphatidic acid). They play a critical role in platelet activation and thrombus formation.³⁸ Equally important, soluble platelet agonists, such as TXA₂, ADP, and serotonin, are released from stimulated platelets that serve to amplify platelet activation and recruit circulating platelets. These agonists activate platelets via G-protein–coupled receptors (GPCRs), a family of 7-transmembrane domain receptors that transmit signals through heterotrimeric G proteins (Figure 2).

The heterotrimeric G proteins consist of 3 subunits (α , β , and γ) that bind to GPCRs in an $\alpha/\beta/\gamma$ complex. On receptor ligation, the α subunit is converted from a GDP-bound form to the active GTP-bound form. Activated $G\alpha$ subunits dissociate from the receptor, and from the β/γ complex, and interact with specific downstream targets to transmit GPCR signals.³⁸ The β/γ complex can also interact with and activate downstream effectors, including PI3K γ .³⁹ Based on the similarity of α subunits, G proteins can be divided into 4 subfamilies: Gq/G11, G12/G13, Gi/Go/Gz, and Gs, each of which is coupled to selective receptors and downstream effectors (Figure 2).³⁸ Platelets express Gq, G12/G13, Gi/Gz, and Gs. G proteins in platelets are coupled to agonist receptors that stimulate platelet activation, with the exception of Gs, which is coupled to receptors for physiological platelet inhibitors (prostaglandin and adenosine) that mediate inhibitory signals by stimulating adenylyl cyclase–dependent

cAMP synthesis (Figure 2). Thrombin-induced platelet activation is mediated via a dual system of G-protein–coupled protease-activated receptors (PARs): PAR1 and PAR4 in humans⁴⁰ and PAR3 and PAR4 in mice.⁴¹ PAR3 appears to sensitize PAR4 to thrombin.^{42,43} PAR1 and PAR4 directly couple to Gq and G12/G13⁴¹ and possibly to Gi.^{44,45} TXA₂ activates platelets via the TXA₂/prostaglandin H2 receptor (TP), which couples to Gq and G13.^{46,47} Serotonin (5-hydroxytryptamine, 5HT) recognizes the Gq-coupled receptor 5HT2A.³⁸ ADP induces platelet activation via P2Y₁ (Gq coupled) and P2Y₁₂ (Gi coupled).^{38,48} The epinephrine receptor (α 2) in platelets is reportedly coupled to Gz, another Gi subtype.⁴⁹

Gq-Mediated Signaling

Gq transmits cellular signals mainly through its interaction and stimulation of PLC β . Gq signaling is important for GPCR-stimulated platelet granule secretion, integrin activation, and consequent platelet aggregation.⁵⁰ Deletion of Gq causes defects in platelet secretion and aggregation in response to a variety of agonists, including thrombin, ADP, TXA₂ analogue U46619, and even collagen (probably because of the dependence of the collagen signaling pathway on TXA₂).⁵⁰ In addition, Gq is important in ADP-induced platelet shape change,⁵⁰ probably by stimulating calcium/calmodulin- and/or RhoA-dependent contractile signaling.⁵¹

Gi-Mediated Signaling

Although Gq is required for platelet activation induced by GPCR agonists, it is neither sufficient for platelet aggregation induced by ADP nor for optimal platelet response induced by TXA₂ or low-dose thrombin. The Gi-coupled ADP receptor, P2Y₁₂,^{52,53} is also required for ADP-induced platelet activation and promotes platelet activation induced by TXA₂ and low-dose thrombin.^{45,54} However, it remains controversial whether the thrombin receptors are coupled to Gi directly or indirectly via P2Y₁₂.^{44,45} The role of Gi-coupled receptors in promoting platelet activation is consistent with the inhibitory effect of Gi on cAMP synthesis, which relieves the inhibitory effect of cAMP-dependent protein kinase on platelet activation. More important, P2Y₁₂-coupled Gi is a major mechanism responsible for the activation of PI3K, particularly β/γ subunit-activated PI3K γ , in platelets^{55,56} and subsequent activation of the small GTPase Rap1b,^{57,58} a critical mediator of integrin activation.

G13 Signaling

Platelets express both G α 12 and G α 13⁵⁹; however, only G α 13-knockout platelets show reduced and unstable platelet aggregation induced by low-dose thrombin and the TXA₂ analogue U46619. G α 13-knockout platelets have reduced granule secretion that is induced by U46619 but not thrombin.⁶⁰ Shape change induced by these agonists is also reduced in G α 13-knockout platelets. GTP-bound G α 13 interacts with and activates guanine nucleotide exchange factors (GEFs) for the small G-protein RhoA, such as p115RhoGEF, which subsequently converts RhoA into the active GTP-bound form.⁶¹ RhoA activates Rho kinase, which phosphorylates and inhibits myosin light chain phosphatase,⁶² thus enhancing

myosin light chain phosphorylation and myosin light chain-dependent contraction. Therefore, G13 stimulates platelet shape change and granule secretion.⁶² Interestingly, $G\alpha_{13}$ deficiency causes more dramatic defects in platelet adhesion and in hemostasis and thrombosis in vivo, relative to its effects on integrin activation, aggregation, and granule secretion in vitro, suggesting an additional role of $G\alpha_{13}$ in platelet function.⁶⁰ Indeed, $G\alpha_{13}$ binds to the cytoplasmic domain of integrin β_3 and plays a critical role in integrin outside-in signaling.⁶³

Common Platelet Activation Signaling and Amplification Pathways

Although the initial signaling mechanisms of various platelet receptors differ, they ultimately converge into common intracellular signaling events. In particular, almost all agonists induce activation of PLC. For example, PLC γ and PLC β are activated by the ITAM and Gq pathways, respectively.⁶⁴ PLC catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate to release inositol trisphosphate (IP3) and diacylglycerol (DAG), which activate calcium mobilization and protein kinase C (PKC), respectively. Intracellular calcium and DAG together also activate calcium and DAG-regulated GEF 1 (CalDAG-GEF1), a Rap1 GEF important in integrin signaling.⁶⁵

Calcium Signaling

The critical role of cytosolic calcium in platelet activation and function has been known for many years. Agonist-induced calcium elevation is mainly induced by inositol trisphosphate receptor-mediated release of calcium from intracellular stores and store-operated calcium entry from outside of platelets.^{66,67} A role for store-independent calcium entry has also been shown.⁶⁶ Canonical transient potential channels and the calcium release-activated channel (Orai1) have been shown to mediate calcium entry.^{66,67} Elevation of calcium levels activates multiple signaling events and molecules, including actin-myosin interaction, PKC, calmodulin, NO synthases, and calcium-dependent proteases. Recently, CalDAG-GEF1 has mediated several important Ca^{2+} responses, including Rap1 activation, extracellular signal-regulated kinase activation, TXA₂ synthesis, and granule secretion.⁶⁷ Calcium elevation also positively regulates SFKs and the PI3K/Akt signaling pathway.⁶⁸

Protein Kinase C

Platelets express several isoforms of the PKC family, including the classical (or conventional) PKC isoforms α and β (calcium and DAG dependent), the novel PKC isoforms δ , θ , and η (DAG dependent and calcium independent), and an atypical PKC isoform ζ (calcium and DAG independent).^{69–73} Another novel PKC, PKC ε , is detectable in mouse, but not human platelets.⁷⁴ Classical PKCs, particularly PKC α , play a critical and general role in platelet granule secretion and secretion-dependent aggregation. PKC α has also been shown to regulate Rap1 and integrin signaling in a reconstituted Chinese hamster ovary cell model.⁷⁵ PKC δ and θ promote dense granule secretion in response to thrombin receptor agonists^{69,71,72}; however, their roles in GPVI-mediated secre-

tion and aggregation are controversial. PKC δ has been reported to negatively regulate GPVI-induced dense granule secretion^{69,72} or to have no effect.⁷³ PKC θ has been shown to promote GPVI-dependent platelet granule secretion and aggregation by one group,⁷¹ but to negatively regulate GPVI-mediated granule secretion and platelet activation by other groups.^{76,77} Pleckstrin is a major PKC substrate and may possibly be involved in cytoskeleton regulation.⁷⁸

Signals Leading to Granule Secretion and Secretion-Dependent Signal Amplification

A common platelet response to all agonists is the secretion of granule contents. Platelets contain 3 major types of granules: α -granules, containing adhesion proteins (eg, fibrinogen, VWF, coagulation and fibrinolytic factors, cytokines, growth factors, and adhesion receptors); dense granules, containing nucleotides (eg, ADP, ATP, and GTP; serotonin; histamine; pyrophosphates; and divalent cations); and lysosomes, containing a host of proteolytic enzymes.⁷⁹ Granule secretion plays critical roles in the amplification of platelet activation, the recruitment of circulating platelets into aggregates, and thrombus stabilization.^{79,80} Thus, it can be considered a signaling amplification mechanism. Granule secretion also plays important roles in inflammation, atherosclerosis, host defense, wound healing, angiogenesis, and malignancy.⁸¹ Granule secretion requires fusion between plasma and granule (vesicle) membranes, which is mediated by protein complexes of vesicle-soluble N-ethylmaleimide-sensitive fusion protein attachment receptor (v-SNARE) proteins (mainly vesicle associated membrane protein [VAMP]-8 in platelets) and plasma membrane (target)-SNARE (mainly syntaxin and synaptosome-associated protein-23 in platelets), as reviewed elsewhere.⁷⁹ The interaction between SNARE proteins is regulated by their phosphorylation and involves small GTPases, such as Rab27. There are multiple signaling events and pathways that are important in stimulating granule secretion: (1) calcium signaling; (2) PKC-dependent phosphorylation and regulation of SNARE complexes⁷⁰; (3) integrin outside-in signaling; (4) TXA₂ generation, which is important in granule secretion induced by ADP, VWF, and collagen; (5) signaling via the small GTPases Rac-1 and RhoA^{82,83}; (6) activation of SFKs, particularly Lyn^{84,85}; (7) the PI3K/Akt signaling pathway^{56,86–89}; (8) the NO/cGMP/PKG pathway^{90,91}; and (9) the signaling pathways of MAPK isoforms p38, ERK, and JNK.^{92,93} Recent studies suggest that SFK Lyn activates the PI3K/Akt pathway.⁸⁵ PI3K and Akt mediate granule secretion primarily by activating the NO/cGMP/PKG pathway, which stimulates granule secretion through the activation of MAPKs and phosphorylation of SNARE proteins.^{90–92}

Integrin Signaling

Inside-Out Signaling

Platelets express integrins $\alpha_{IIb}\beta_3$ (fibrinogen receptor), $\alpha_v\beta_3$ (vitronectin receptor), $\alpha_2\beta_1$ (collagen receptor), $\alpha_5\beta_1$ (fibronectin receptor), and $\alpha_6\beta_1$ (laminin receptor). These integrins share similar signal transduction mechanisms. The most abundant integrin in platelets, $\alpha_{IIb}\beta_3$, is normally kept in a resting or low-affinity state in circulating platelets, but transforms into a high-affinity “activated” state after platelet




Figure 3. $G\alpha_{13}$ -dependent cross talk between GPCR signaling and integrin outside-in signaling in regulating RhoA activity in platelets. Data are adapted from Gong et al.⁶³ RhoGEF, rho guanine nucleotide exchange factor; RhoGAP, rho GTPase-activating protein.

activation. Activated $\alpha_{IIb}\beta_3$, by binding to its ligands (fibrinogen, VWF, and many matrix proteins containing RGD-like sequences), mediates stable platelet adhesion, platelet aggregation, and thrombus formation. The integrin-proximal intracellular signaling mechanism that induces changes in the extracellular ligand binding domain of integrins from a “low-affinity” state to the activated state is referred to as “inside-out” signaling.^{1,94} Inside-out signaling requires the binding of talin and kindlins to the cytoplasmic domain of β_3 .^{95–97} The relationship between talin and kindlins in inside-out signaling is still being clarified. The binding sites in the β_3 cytoplasmic domain for talin and kindlins appear distinct. Talin binds to the membrane proximal region and the NPLY motif of β_3 ,^{98–100} whereas kindlins bind to the sequences around the C-terminal NXXY motif.^{96,97} Recent studies support the hypothesis that kindlins regulate talin-integrin interaction and cooperate with talin to stimulate inside-out signaling.⁹⁷ The binding of talin head domain to β_3 appears to be sufficient to trigger disruption of the interaction between the membrane proximal regions of the cytoplasmic domains of α_{IIb} and β_3 and conformational changes in $\alpha_{IIb}\beta_3$ that propagate to the extracellular ligand-binding domain, transforming integrin $\alpha_{IIb}\beta_3$ into the “active” conformation.^{95,101,102} The change of conformation in $\alpha_{IIb}\beta_3$ from a bent to an extended form may result in the activation of the ligand-binding function of the integrin.¹ A possible role of integrin transmembrane domain interactions in this process has also been suggested.¹⁰³

Recent studies suggest that CalDAG-GEF1 and its downstream target, Rap1, play an important role in inside-out

signaling,^{65,104} providing a possible link between these signaling events and integrin inside-out signaling. CalDAG-GEF1 converts Rap1, a member of the Ras family of small GTPases, from the GDP-bound form to the active GTP-bound form, which interacts with the Rap1-GTP-interacting adaptor molecule (RIAM). The role of CalDAG-GEF1/Rap1 in integrin inside-out signaling is consistent with the data that RIAM promotes $\alpha_{IIb}\beta_3$ -talin interaction and integrin activation.¹⁰⁵ The predominant Rap1 isoform expressed in platelets is Rap1b. However, platelets lacking Rap1b¹⁰⁴ or CalDAG-GEF1⁶⁵ show only partial defects in $\alpha_{IIb}\beta_3$ -dependent platelet aggregation, suggesting that neither Rap1b nor CalDAG-GEF1 is fully responsible for inside-out signaling. It remains to be determined whether other isoforms of CalDAG-GEF and Rap1 or alternative pathways are also important in inside-out signaling.

Outside-In Signaling

Ligand binding to integrin $\alpha_{IIb}\beta_3$ mediates platelet adhesion and aggregation and initiates a series of intracellular signaling events (“outside-in” signaling), leading to platelet spreading, granule secretion, stable adhesion, and clot retraction.¹⁰⁶ After ligand binding, integrins undergo “a ligand-induced conformational change” that can be propagated outside-in to the cytoplasmic domain.¹⁰⁷ However, although ligand-induced conformational changes of $\alpha_{IIb}\beta_3$ occur on the binding of multimeric macromolecular ligands, such as fibrinogen, or monomeric peptide ligands, such as RGDS, a significant cellular response only occurs with multimeric macromolecular ligands, suggesting that ligand-induced re-

ceptor clustering may be important for transmitting outside-in signals. The most proximal signaling event that occurs after integrin ligation is the binding of the G protein subunit $G\alpha_{13}$ to the cytoplasmic domain of β_3 .⁶³ The interaction of $G\alpha_{13}$ with β_3 stimulates the activation of SFKs,⁶³ particularly β_3 -bound c-Src,¹⁰⁸ thus initiating the SFK-dependent signals required for outside-in signaling. SFKs mediate outside-in signaling through the following mechanisms. (1) SFK-mediated phosphorylation of the 2 NXXY motifs in the cytoplasmic domain of β_3 is critically important for outside-in signaling.¹⁰⁹ Phosphorylation at Y747 negatively regulates talin binding.¹¹⁰ Phosphorylation at Y759 protects β_3 from calpain cleavage.¹¹¹ β_3 -Tyrosine phosphorylation may also promote β_3 interaction with intracellular molecules, such as myosin heavy chain and adapter protein SHC.¹¹² (2) c-Src phosphorylates and activates a major RhoA GTPase-activating protein, p190 Rho GTPase-activating protein, which inactivates RhoA.¹¹³ By this mechanism, the β_3 -bound c-Src mediates transient RhoA inhibition during the early phase of platelet spreading on fibrinogen.^{63,114} Inhibition of c-Src or deletion of the c-Src binding site in β_3 abolishes integrin-mediated cell spreading in Chinese hamster ovary cells and platelets,^{114,115} which can be reversed by RhoA inhibitors, suggesting that c-Src-mediated transient RhoA inhibition is critical for integrin outside-in signaling, leading to platelet spreading. Interestingly, the c-Src-mediated inhibition of RhoA requires the binding of c-Src to a specific site at the C-terminus of β_3 that is sensitive to cleavage by a calcium-dependent protease (calpain).¹¹⁴ After thrombus formation and coagulation, cleavage of β_3 by calpain at this site abolishes the interaction of c-Src with β_3 , which relieves the inhibitory effect of β_3 -bound c-Src on RhoA, leading to activation of RhoA and clot retraction.¹¹⁴ (3) SFKs activate Syk.¹⁰⁸ In human platelets, this can be mediated through phosphorylation of Fc γ RIIA,¹¹⁶ which recruits Syk into the integrin signaling complex. Syk activation may also involve its interaction with the β_3 cytoplasmic domain.¹¹⁷ Syk facilitates the assembly of an SLP-76/LAT/Btk/Vav complex that mediates activation of PLC γ 2 and subsequent platelet activation events in a manner analogous to the GPVI-mediated ITAM signaling pathway.^{116–118}

Cross Talk Between GPCR Signaling and Integrin Outside-In Signaling

Integrin outside-in signaling amplifies platelet responses to GPCR agonists. Conversely, GPCR signaling promotes integrin outside-in signaling. For example, platelet spreading on fibrinogen is greatly enhanced when platelets are treated with GPCR agonists. This is because GPCRs induce integrin activation and directly regulate integrin outside-in signaling. In particular, GPCR-mediated activation of $G\alpha_{13}$, although not directly responsible for integrin activation, greatly enhances the interaction of $G\alpha_{13}$ with β_3 , which is required for outside-in signaling.⁶³ More important, the GPCR/ $G\alpha_{13}$ and integrin outside-in signaling pathways coordinate with each other to dynamically regulate RhoA-dependent signaling in platelets. The ability of these 2 signaling pathways to cross talk and dynamically regulate RhoA-dependent signaling is

critical for the processes of shape change, granule secretion, spreading, and clot retraction in platelets (Figure 3).

Conclusions

Significant progress has been made in recent years in our understanding of platelet signal transduction during adhesion and activation. Thus, we face an increasingly complex signaling network in platelets and new frontiers to be explored. Many new opportunities for discovery lie in the molecular details of the apparently well-defined signaling pathways. With the goal of fighting thrombotic and hemorrhagic diseases in mind, it is intriguing to know whether further dissection of the molecular mechanisms of integrin signaling may lead to the development of new inhibitors that specifically inhibit outside-in signaling-mediated amplification of platelet activation and platelet recruitment without blocking the ligand-binding function of integrins critically important in hemostasis. Also, the importance of the cross talk between various adhesion receptor signaling pathways and G-protein-coupled signaling pathways is increasingly evident. Understanding the cross talk between these pathways may provide insight into the phenomenon of “resistance” to existing platelet inhibitors and may allow for the development of new therapeutic agents that are more effective in treating thrombosis, with less bleeding side effect. Finally, the elucidation of platelet signaling pathways that contribute to the functions of platelets in events beyond hemostasis and thrombosis, such as those discussed in other articles in this series, may reveal new therapeutic targets for the treatment of disorders such as inflammatory diseases, atherosclerosis, and cancer.

Sources of Funding

This study was supported by grant P20 RR021954 from the National Institutes of Health/National Center for Research Resources Centers of Biomedical Research Excellence in Obesity and Cardiovascular Disease (Dr Li); and grants HL062350, HL068819, and HL080264 from the National Heart, Lung, and Blood Institute (Dr Du).

Disclosures

Dr Du, University of Illinois, Chicago, holds patents relevant to the topic of this review.

References

1. Collier BS, Shattil SJ. The GPIIb/IIIa (integrin α IIb β 3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. *Blood*. 2008;112:3011–3025.
2. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhilb SR, Becker RC. G-protein-coupled receptors as signaling targets for antiplatelet therapy. *Arterioscler Thromb Vasc Biol*. 2009;29:449–457.
3. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, Lee DM. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. *Science*. 2010;327:580–583.
4. Leslie M. Cell biology: beyond clotting: the powers of platelets. *Science*. 2010;328:562–564.
5. Clemetson KJ, Clemetson JM. Platelet collagen receptors. *Thromb Haemost*. 2001;86:189–197.
6. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. *J Biol Chem*. 1997;272:23528–23531.
7. Reth M. Antigen receptor tail clue. *Nature*. 1989;338:383–384.
8. Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen

- receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. *J Exp Med*. 1998;188:267–276.
9. Quek LS, Pasquet JM, Hers I, Cornell R, Knight G, Barnes M, Hibbs ML, Dunn AR, Lowell CA, Watson SP. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. *Blood*. 2000;96:4246–4253.
10. Senis YA, Tomlinson MG, Ellison S, Mazharian A, Lim J, Zhao Y, Kornerup KN, Auger JM, Thomas SG, Dhanjal T, Kalina N, Zhu JW, Weiss A, Watson SP. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. *Blood*. 2009;113:4942–4954.
11. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. *J Thromb Haemost*. 2005;3:1752–1762.
12. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? *Blood*. 2003;102:449–461.
13. Pasquet JM, Bobe R, Gross B, Gratacap MP, Tomlinson MG, Payrastre B, Watson SP. A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets. *Biochem J*. 1999;342:171–177.
14. Watanabe N, Nakajima H, Suzuki H, Oda A, Matsubara Y, Moroi M, Terauchi Y, Kadowaki T, Suzuki H, Koyasu S, Ikeda Y, Handa M. Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation. *Blood*. 2003;102:541–548.
15. Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, Olieslagers S, Chrzanowska-Wodnicka MB, Lillian R, Schoenwaelder S, Koyasu S, Sage SO, Jackson SP, Heemskerk JW. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. *J Biol Chem*. 2009;284:33750–33762.
16. Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. *Arterioscler Thromb Vasc Biol*. 2003;23:953–964.
17. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell*. 1996;84:289–297.
18. Lopez JA, Dong JF. Structure and function of the glycoprotein Ib-IX-V complex. *Curr Opin Hematol*. 1997;4:323–329.
19. Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. *Curr Opin Hematol*. 2007;14:262–269.
20. Yago T, Lou J, Wu T, Yang J, Miner JJ, Coburn L, Lopez JA, Cruz MA, Dong JF, McIntire LV, McEver RP, Zhu C. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. *J Clin Invest*. 2008;118:3195–3207.
21. Kim J, Zhang CZ, Zhang X, Springer TA. A mechanically stabilized receptor-ligand flex-bond important in the vasculature. *Nature*. 2010;466:992–995.
22. Sullam PM, Hyun WC, Szollosi J, Dong J, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane. *J Biol Chem*. 1998;273:5331–5336.
23. Wu Y, Suzuki-Inoue K, Satoh K, Asazuma N, Yatomi Y, Berndt MC, Ozaki Y. Role of Fc receptor gamma-chain in platelet glycoprotein Ib-mediated signaling. *Blood*. 2001;97:3836–3845.
24. Liu J, Pestina TI, Berndt MC, Jackson CW, Gartner TK. Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIb beta3- and aggregation-independent manner. *Blood*. 2005;106:2750–2756.
25. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. *Blood*. 2006;108:2596–2603.
26. Kasirer-Friede A, Cozzi MR, Mazzucato M, De Marco L, Ruggeri ZM, Shattil SJ. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. *Blood*. 2004;103:3403–3411.
27. Li Z, Xi X, Du X. A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIb beta3. *J Biol Chem*. 2001;276:42226–42232.
28. Li Z, Zhang G, Feil R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3. *Blood*. 2006;107:965–972.
29. Garcia A, Quinton TM, Dorsam RT, Kunapuli SP. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. *Blood*. 2005;106:3410–3414.
30. Yin H, Stojanovic A, Hay N, Du X. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. *Blood*. 2008;111:658–665.
31. Mu FT, Cranmer SL, Andrews RK, Berndt MC. Functional association of phosphoinositide-3-kinase with platelet glycoprotein Ibalpha, the major ligand-binding subunit of the glycoprotein Ib-IX-V complex. *J Thromb Haemost*. 2010;8:324–330.
32. Yap CL, Anderson KE, Hughan SC, Doppeide SM, Salem HH, Jackson SP. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(Ib)beta(3). *Blood*. 2002;99:151–158.
33. Yin H, Liu J, Li Z, Berndt MC, Lowell CA, Du X. Src family tyrosine kinase Lyn mediates VWF/GPIb-IX-induced platelet activation via the cGMP signaling pathway. *Blood*. 2008;112:1139–1146.
34. Mazzucato M, Pradella P, Cozzi MR, De Marco L, Ruggeri ZM. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. *Blood*. 2002;100:2793–2800.
35. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. *Cell*. 2003;112:77–86.
36. Riba R, Oberprieler NG, Roberts W, Naseem KM. Von Willebrand factor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein Ib-dependent mechanism. *J Thromb Haemost*. 2006;4:2636–2644.
37. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Muller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. *J Thromb Haemost*. 2008;6:1376–1384.
38. Offermanns S. Activation of platelet function through G protein-coupled receptors. *Circ Res*. 2006;99:1293–1304.
39. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J, Smrcka AS, Thelen M, Cadwallader K, Tempst P, Hawkins PT. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. *Cell*. 1997;89:105–114.
40. Coughlin SR. How the protease thrombin talks to cells. *Proc Natl Acad Sci U S A*. 1999;96:11023–11027.
41. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. *Nature*. 1998;394:690–694.
42. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. *Nature*. 2000;404:609–613.
43. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. *Nature*. 2001;413:74–78.
44. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. *J Thromb Haemost*. 2005;3:1800–1814.
45. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. *Blood*. 2002;99:3629–3636.
46. Knezevic I, Borg C, Le Breton GC. Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. *J Biol Chem*. 1993;268:26011–26017.
47. Djellas Y, Manganello JM, Antonakis K, Le Breton GC. Identification of Galpha13 as one of the G-proteins that couple to human platelet thromboxane A2 receptors. *J Biol Chem*. 1999;274:14325–14330.
48. Ohlmann P, Laugwitz KL, Nurnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C. The human platelet ADP receptor activates Gi2 proteins. *Biochem J*. 1995;312:775–779.
49. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, Manning D, Poncz M, Lucki I, Blendy JA, Brass LF. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. *Proc Natl Acad Sci U S A*. 2000;97:9984–9989.
50. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. *Nature*. 1997;389:183–186.
51. Vogt S, Grosse R, Schultz G, Offermanns S. Receptor-dependent RhoA activation in G12/G13-deficient cells: genetic evidence for an involvement of Gq/G11. *J Biol Chem*. 2003;278:28743–28749.

52. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature*. 2001;409:202–207.
53. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. *J Clin Invest*. 2001;107:1591–1598.
54. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation: essential role for p2t(ac) and alpha(2a) receptors. *J Biol Chem*. 1999;274:29108–29114.
55. Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, Wymann M, Montruccio G. Resistance to thromboembolism in PI3Kgamma-deficient mice. *FASEB J*. 2001;15:2019–2021.
56. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. *J Biol Chem*. 2003;278:30725–30731.
57. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. *J Biol Chem*. 2002;277:23382–23390.
58. Lova P, Paganini S, Hirsch E, Barberis L, Wymann M, Sinigaglia F, Balduini C, Torti M. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. *J Biol Chem*. 2003;278:131–138.
59. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. *Proc Natl Acad Sci U S A*. 1994;91:504–508.
60. Moers A, Nieswandt B, Massberg S, Wettschreck N, Gruner S, Konrad I, Schulte V, Aktas B, Gratacap MP, Simon MI, Gawaz M, Offermanns S. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. *Nat Med*. 2003;9:1418–1422.
61. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, Sternweis PC. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. *Science*. 1998;280:2109–2111.
62. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. *J Cell Biol*. 1999;144:745–754.
63. Gong H, Shen B, Flevaris P, Chow C, Lam SC, Voyno-Yasenetskaya TA, Kozasa T, Du X. G protein subunit Galpha13 binds to integrin alphaIIb beta3 and mediates integrin “outside-in” signaling. *Science*. 2010;327:340–343.
64. Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. *J Thromb Haemost*. 2009;7:1057–1066.
65. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, Graybiel AM. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. *Nat Med*. 2004;10:982–986.
66. Hassock SR, Zhu MX, Trost C, Flockerzi V, Authi KS. Expression and role of TRPC proteins in human platelets: evidence that TRPC6 forms the store-independent calcium entry channel. *Blood*. 2002;100:2801–2811.
67. Bergmeier W, Stefanini L. Novel molecules in calcium signaling in platelets. *J Thromb Haemost*. 2009;7(suppl 1):187–190.
68. Xiang B, Zhang G, Liu J, Morris AJ, Smyth SS, Gartner TK, Li Z. A G-independent mechanism mediating Akt phosphorylation in platelets. *J Thromb Haemost*. 2010;8:2032–2041.
69. Murugappan S, Tuluc F, Dorsam RT, Shankar H, Kunapuli SP. Differential role of protein kinase C delta isoform in agonist-induced dense granule secretion in human platelets. *J Biol Chem*. 2004;279:2360–2367.
70. Konopatskaya O, Gilio K, Harper MT, Zhao Y, Cosemans JM, Karim ZA, Whiteheart SW, Molkenin JD, Verkade P, Watson SP, Heemskerk JW, Poole AW. PKCalpha regulates platelet granule secretion and thrombus formation in mice. *J Clin Invest*. 2009;119:399–407.
71. Nagy B Jr, Bhavaraju K, Getz T, Bynagari YS, Kim S, Kunapuli SP. Impaired activation of platelets lacking protein kinase C-theta isoform. *Blood*. 2009;113:2557–2567.
72. Chari R, Getz T, Nagy B Jr, Bhavaraju K, Mao Y, Bynagari YS, Murugappan S, Nakayama K, Kunapuli SP. Protein kinase Cδ differentially regulates platelet functional responses. *Arterioscler Thromb Vasc Biol*. 2009;29:699–705.
73. Pula G, Schuh K, Nakayama K, Nakayama KI, Walter U, Poole AW. PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. *Blood*. 2006;108:4035–4044.
74. Pears CJ, Thornber K, Auger JM, Hughes CE, Grygielska B, Protty MB, Pearce AC, Watson SP. Differential roles of the PKC novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. *PLoS One*. 2008;3:e3793.
75. Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, Puzon-McLaughlin W, Lafuente EM, Boussiotis VA, Shattil SJ, Ginsberg MH. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIb beta3. *Curr Biol*. 2006;16:1796–1806.
76. Hall KJ, Harper MT, Gilio K, Cosemans JM, Heemskerk JW, Poole AW. Genetic analysis of the role of protein kinase Ctheta in platelet function and thrombus formation. *PLoS One*. 2008;3:e3277.
77. Harper MT, Poole AW. Protein kinase Ctheta negatively regulates store-independent Ca2+ entry and phosphatidylserine exposure downstream of glycoprotein VI in platelets. *J Biol Chem*. 2010;285:19865–19873.
78. Lian L, Wang Y, Flick M, Choi J, Scott EW, Degen J, Lemmon MA, Abrams CS. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. *Blood*. 2009;113:3577–3584.
79. Ren Q, Ye S, Whiteheart SW. The platelet release reaction: just when you thought platelet secretion was simple. *Curr Opin Hematol*. 2008;15:537–541.
80. Reed GL, Fitzgerald ML, Polgar J. Molecular mechanisms of platelet exocytosis: insights into the “secrete” life of thrombocytes. *Blood*. 2000;96:3334–3342.
81. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. *Blood Rev*. 2009;23:177–189.
82. Huang JS, Dong L, Kozasa T, Le Breton GC. Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion. *J Biol Chem*. 2007;282:10210–10222.
83. Akbar H, Kim J, Funk K, Cancelas JA, Shang X, Chen L, Johnson JF, Williams DA, Zheng Y. Genetic and pharmacologic evidence that Rac1 GTPase is involved in regulation of platelet secretion and aggregation. *J Thromb Haemost*. 2007;5:1747–1755.
84. Cho MJ, Pestina TI, Steward SA, Lowell CA, Jackson CW, Gartner TK. Role of the Src family kinase Lyn in TxA2 production, adenosine diphosphate secretion, Akt phosphorylation, and irreversible aggregation in platelets stimulated with gamma-thrombin. *Blood*. 2002;99:2442–2447.
85. Li Z, Zhang G, Liu J, Stojanovic A, Ruan C, Lowell CA, Du X. An important role of the SRC family kinase Lyn in stimulating platelet granule secretion. *J Biol Chem*. 2010;285:12559–12570.
86. Kovacsics TJ, Bachelot C, Toker A, Vlahos CJ, Duckworth B, Cantley LC, Hartwig JH. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. *J Biol Chem*. 1995;270:11358–11366.
87. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. *J Clin Invest*. 2004;113:441–450.
88. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. *Blood*. 2004;104:1703–1710.
89. Stojanovic A, Marjanovic JA, Brovkovich VM, Peng X, Hay N, Skidgel RA, Du X. A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. *J Biol Chem*. 2006;281:16333–16339.
90. Li Z, Zhang G, Marjanovic JA, Ruan C, Du X. A platelet secretion pathway mediated by cGMP-dependent protein kinase. *J Biol Chem*. 2004;279:42469–42475.
91. Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. *J Exp Med*. 2004;199:347–356.
92. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractive signaling pathway. *Blood*. 2009;113:893–901.
93. Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, Davis RJ, Rosa JP, Bryckaert M. Platelet JNK1 is involved in secretion and thrombus formation. *Blood*. 2010;115:4083–4092.
94. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. *Nat Rev Mol Cell Biol*. 2010;11:288–300.

95. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, Ginsberg MH, Calderwood DA. Talin binding to integrin beta tails: a final common step in integrin activation. *Science*. 2003;302:103–106.
96. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. *Nat Med*. 2008;14:325–330.
97. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. *J Cell Biol*. 2008;181:439–446.
98. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. *J Biol Chem*. 1999;274:28071–28074.
99. Patil S, Jedsadayanmata A, Wencel-Drake JD, Wang W, Knezevic I, Lam SC. Identification of a talin-binding site in the integrin beta(3) subunit distinct from the NPLY regulatory motif of post-ligand binding functions: the talin n-terminal head domain interacts with the membrane-proximal region of the beta(3) cytoplasmic tail. *J Biol Chem*. 1999;274:28575–28583.
100. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, Campbell ID. Structural basis of integrin activation by talin. *Cell*. 2007;128:171–182.
101. Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas T, Plow E, Qin J. A structural mechanism of integrin alpha(IIB)beta(3) “inside-out” activation as regulated by its cytoplasmic face. *Cell*. 2002;110:587–597.
102. Ye F, Hu G, Taylor D, Ratnikov B, Bobkov AA, McLean MA, Sligar SG, Taylor KA, Ginsberg MH. Recreation of the terminal events in physiological integrin activation. *J Cell Biol*. 2010;188:157–173.
103. Li R, Mitra N, Gratkowski H, Vilaire G, Litvinov R, Nagasami C, Weisel JW, Lear JD, DeGrado WF, Bennett JS. Activation of integrin alphaIIb beta3 by modulation of transmembrane helix associations. *Science*. 2003;300:795–798.
104. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC II. Rap1b is required for normal platelet function and hemostasis in mice. *J Clin Invest*. 2005;115:680–687.
105. Lafuente EM, van Puijenbroek AA, Krause M, Carman CV, Freeman GJ, Berezovskaya A, Constantine E, Springer TA, Gertler FB, Bousiotis VA. RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. *Dev Cell*. 2004;7:585–595.
106. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. *Blood*. 2004;104:1606–1615.
107. Leisner TM, Wencel-Drake JD, Wang W, Lam SC. Bidirectional transmembrane modulation of integrin alphaIIb beta3 conformations. *J Biol Chem*. 1999;274:12945–12949.
108. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ. Coordinate interactions of Csk, Src, and Syk kinases with alphaIIb beta3 initiate integrin signaling to the cytoskeleton. *J Cell Biol*. 2002;157:265–275.
109. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIb beta3 signalling and platelet function. *Nature*. 1999;401:808–811.
110. Anthis NJ, Haling JR, Oxley CL, Memo M, Wegener KL, Lim CJ, Ginsberg MH, Campbell ID. Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. *J Biol Chem*. 2009;284:36700–36710.
111. Xi X, Flevaris P, Stojanovic A, Chishti A, Phillips DR, Lam SC, Du X. Tyrosine phosphorylation of the integrin beta 3 subunit regulates beta 3 cleavage by calpain. *J Biol Chem*. 2006;281:29426–29430.
112. Jenkins AL, Nannizzi-Alaimo L, Silver D, Sellers JR, Ginsberg MH, Law DA, Phillips DR. Tyrosine phosphorylation of the beta3 cytoplasmic domain mediates integrin-cytoskeletal interactions. *J Biol Chem*. 1998;273:13878–13885.
113. Arthur WT, Petch LA, Burrridge K. Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism. *Curr Biol*. 2000;10:719–722.
114. Flevaris P, Stojanovic A, Gong H, Chishti A, Welch E, Du X. A molecular switch that controls cell spreading and retraction. *J Cell Biol*. 2007;179:553–565.
115. Ablooglu AJ, Kang J, Petrich BG, Ginsberg MH, Shattil SJ. Anti-thrombotic effects of targeting alphaIIb beta3 signaling in platelets. *Blood*. 2009;113:3585–3592.
116. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of Fc gammaRIIa as the ITAM-bearing receptor mediating alphaIIb beta3 outside-in integrin signaling in human platelets. *Blood*. 2008;112:2780–2786.
117. Woodside DG, Obergfell A, Leng L, Wilsbacher JL, Miranti CK, Brugge JS, Shattil SJ, Ginsberg MH. Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains. *Curr Biol*. 2001;11:1799–1804.
118. Abtahian F, Bezman N, Clemens R, Sebzda E, Cheng L, Shattil SJ, Kahn ML, Koretzky GA. Evidence for the requirement of ITAM domains but not SLP-76/Gads interaction for integrin signaling in hematopoietic cells. *Mol Cell Biol*. 2006;26:6936–6949.

Arteriosclerosis, Thrombosis, and Vascular Biology



JOURNAL OF THE AMERICAN HEART ASSOCIATION

Signaling During Platelet Adhesion and Activation

Zhenyu Li, M. Keegan Delaney, Kelly A. O'Brien and Xiaoping Du

Arterioscler Thromb Vasc Biol. 2010;30:2341-2349; originally published online November 11, 2010;

doi: 10.1161/ATVBAHA.110.207522

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2010 American Heart Association, Inc. All rights reserved.

Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://atvb.ahajournals.org/content/30/12/2341>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:
<http://atvb.ahajournals.org/subscriptions/>